• International expert opinion and implementation guide outlines ketamine and esketamine treatment parameters that set the standard for the clinical implementation of these rapid-acting therapies in treatment-resistant depression
• Guidelines published in the Official Journal of the American Psychiatric Association make Braxia Scientific an international leader in the rapidly evolving industry of ketamine, esketamine, and fast-acting antidepressants

TORONTO, June 9, 2021 / PRNewswire / – Braxia Scientific Corp. (“Braxia” or the “Company”), (CSE: BRAX) (OTC: BRAXF) (FWB: 496), a medical research company with clinics offering new ketamine treatments for people with depression and depression. related disorders, is pleased to announce the American Journal of Psychiatry, the world’s most widely read psychiatric journal, has published the International Expert Opinion and Implementation Guidance (the “Guidelines”) for the clinical use of ketamine and rapid-acting esketamine for treatment-resistant depression (TRD).

The guidelines were developed and led by Braxia CEO Dr. Roger S. McIntyre, MD, and Medical Director of Braxia Health, Joshua Rosenblat, MD, M. Sc., As well as an international group of 26 medical experts on five continents.

In 2019, esketamine therapy received FDA approval with “breakthrough status” by the FDA. Intravenous (IV) esketamine and ketamine are the first glutamate treatments that have been shown to work quickly in adults with TDD.

“We were encouraged to see increased availability and access to esketamine and ketamine for adults with TDD. We have also been interested in ensuring that the implementation of these rapid-acting therapies is carried out according to the best parameters of science and clinical practice, ”said Dr. Roger S. McIntyre, CEO, Braxia Scientific. “With the growing number of practitioners and community clinics in United States who have expanded their scope of practice to include ketamine and esketamine for treatment-resistant depression, our goal is to support their ability to immediately implement our advice and recommendations to provide their patients with the best chance of achieving safe and effective treatment. “

Dr. Roger S. McIntyre continued: “Our experience of administering ketamine, and more recently esketamine, to a large number of people with treatment-resistant depression since the opening of our first clinic in 2018, has enabled us to inform practitioners, internationally, on safety and evidence – the implementation of these treatments. We believe that the integration of Science with best practices in clinics, as described in our expert opinion and implementation guide, provides a framework for the field and improves the likelihood of success for patients receiving these treatments. “

Dr. Joshua Rosenblat added: “With the guidelines published in the American Journal of Psychiatry, led by psychiatrists at Braxia, we will work with practitioners and healthcare professionals around the world to provide education, share our expertise and best practices. so that patients with treatment-resistant depression receive the highest quality care. “

The guidelines were published in May 2021 in the American Journal of Psychiatry under the title “Synthesize the evidence of ketamine and esketamine for treatment-resistant depression.”

The Guidelines aim to synthesize for treatment providers the available literature regarding the efficacy, safety and tolerability of esketamine and IV ketamine in adults with treatment-resistant depression. An additional objective was to provide guidance for the safe and appropriate implementation of these agents in clinical practice with an emphasis on the practice parameters to be adopted by clinics providing IV esketamine and ketamine.

The full review citation is: Synthesizing the Evidence for Ketamine and Esketamine in Treatment-Resistant Depression: An International Expert Opinion on the Available Evidence and Implementation. McIntyre RS, et al. Am J Psychiatry. 2021 May 1; 178 (5): 383-399. doi: 10.1176 / appi.ajp.2020.20081251

According to the American Journal of Psychiatry (https://ajp.psychiatryonline.org/about), it is the world’s most widely read psychiatric journal, a must-have journal for all psychiatrists and other mental health professionals who need to stay on top of virtually every aspect of psychiatry.

About Braxia Scientific Corp.

Braxia Scientific (CSE: BRAX) (OTC: BRAXF) (FWB: 496), is a medical research company with clinics that provide innovative ketamine treatments for people with depression and related disorders. Through its medical solutions, the Company aims to reduce the disease burden of brain-related mental disorders such as major depressive disorder, among others. Braxia Scientific is primarily focused on (i) owning and operating multidisciplinary clinics providing ketamine treatment for mental health disorders and (ii) research activities related to the discovery and commercialization of new drugs and administration methods. The Company develops ketamine and psilocybin derivatives and other psychedelic products from its IP development platform. Braxia Scientific, through its wholly owned subsidiary, the Canadian Center of Excellence for Rapid Cure Inc., currently operates multidisciplinary community clinics providing rapid onset treatments for depression located in Mississauga, Toronto, Ottawa, and Montreal.

ON BEHALF OF THE BOARD
“Dr. Roger S. McIntyre“
Dr. Roger S. McIntyre
Chairman and CEO

The CSE has not reviewed and accepts no responsibility for the accuracy or relevance of this release.

Caution regarding forward-looking information

This press release contains forward-looking statements within the meaning of applicable securities laws. All statements that are not historical facts, future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations or beliefs of future performance are “forward-looking statements”.

Forward-looking statements include statements about the promise of ketamine and esketamine-based treatments for depression, and the potential of ketamine to treat other emerging psychiatric disorders, for the Company to be a leader in this field, for the Company’s ability to develop its clinical networks, and for the Company to develop and market new drugs and delivery methods.

These forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results, events or developments to differ materially from the future results, events or developments expressed or implied by such forward-looking statements. These risks and uncertainties include, among others, the inability of ketamine to provide the expected health benefits and unintended side effects, reliance on obtaining and maintaining regulatory approvals, including the ” acquisition and renewal of federal, provincial, municipal, local or other licenses and participation in activities which may subsequently be deemed illegal under national or international laws. These factors should be carefully considered and readers are cautioned not to place undue reliance on these forward-looking statements. Although the Company has attempted to identify significant risk factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other risk factors that cause actions, events or results differ from those anticipated, estimated or predicted.

Additional information identifying the risks and uncertainties that could affect the financial results is contained in the documents filed by the Company with the Canadian securities regulators, including the amended and restated registration statement dated April 15, 2021, which are available on www.sedar.com.

There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in forward-looking statements.

View original content to download multimedia: http://www.prnewswire.com/news-releases/american-journal-of-psychiatry-publishes-international-ketamine-and-esketamine-treatment-guidance-led-by-braxia -scientific -PDG-dr-roger-mcintyre-301308890.html

SOURCE Braxia Scientific Corp.

Company codes: OTC-ROSE: BRAXF, CNSX: BRAX, Frankfurt: 496